Vorasidenib is an oral inhibitor of mutant IDH1 and IDH2 glioma cells, specifically designed for brain penetrance, which showed consistent suppression of D-2-hydroxyglutarate (2-HG), the oncometabolite that drives cell proliferation (6) and favors brain-tumor related epilepsy. This evidence concerns the gene IDH1 and central nervous system cancer.